LONDON – The World Health Organization (WHO) has released its COVID-19 R&D roadmap, highlighting the gaps in knowledge about the virus and setting out priorities for research. The organization is now calling on groups around the world to use the document – drawn up by 400 experts – to coordinate their efforts.
A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a vaccine or antiviral treatment to address the rapidly spreading coronavirus, now known as COVID-19, has more than doubled, increasing from about 30 a few weeks ago to 71 as of March 6.
BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced Feb. 24 that it has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released.
Against the backdrop of the global spread of COVID-19, India announced restrictions Tuesday on the export of 26 active pharmaceutical ingredients (APIs) and formulations of those ingredients.
Under steady pressure to accelerate development of vaccines against SARS-CoV-2 and treatments for COVID-19 as the global death toll reached 3,085 people on the afternoon of March 2, biopharma companies continued to detail progress, including in updates at a White House meeting between pharmaceutical executives and administration officials, including President Donald Trump.
Rated the No. 1 most prepared country in the world to tackle an epidemic, the U.S. could see its preparedness put to the test as it responds to the growing COVID-19 outbreak. While the administration is pointing to that rating from a recent global survey to calm fears about the risk in the U.S., the coronavirus emergency is spotlighting cracks in the nation’s preparedness.
BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced this week it that has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released. That is record speed. Other vaccine developers are also working around the clock to respond to the epidemic.
BEIJING – Chinese biotech companies are focusing on fighting the novel coronavirus, now named as COVID-19 by the WHO, after the country’s government called for all possible assistance.
BEIJING – Chinese biotech companies are focusing on fighting the novel coronavirus, now named as COVID-19 by the WHO, after the country’s government called for all possible assistance. With its Trimer-Tag technology, Chengdu-based Sichuan Clover Biopharmaceuticals Inc. is among the first to reveal production of a vaccine candidate against COVID-19.
RSS
